Clinical Trial: A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211776) titled 'A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease' on Oct. 01.

Brief Summary: A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Study Start Date: Dec. 27

Study Type: INTERVENTIONAL

Condition: Thyroid Eye Disease (TED)

Intervention: DRUG: ZL-1109 (VRDN-003)

ZL-1109 subcutaneous injection

DRUG: Placebo

Matching placebo subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Disclaimer: Curated by HT Syndication....